X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (17) 17
human necessities (14) 14
hygiene (14) 14
medical or veterinary science (14) 14
preparations for medical, dental, or toilet purposes (14) 14
chemistry (13) 13
humans (13) 13
metallurgy (13) 13
organic chemistry (13) 13
peptides (13) 13
female (10) 10
oncology (10) 10
male (9) 9
analysis (8) 8
middle aged (8) 8
physics (8) 8
aged (7) 7
experiment (6) 6
high energy physics - experiment (6) 6
adult (5) 5
cancer (5) 5
endothelial growth-factor (5) 5
hep (5) 5
particle physics (5) 5
patients (5) 5
angiogenesis (4) 4
bevacizumab (4) 4
care and treatment (4) 4
pharmacokinetics (4) 4
physics - high energy physics - experiment (4) 4
treatment outcome (4) 4
vascular endothelial growth factor (4) 4
animals (3) 3
clinical trials (3) 3
drug therapy (3) 3
farms (3) 3
health aspects (3) 3
immunology (3) 3
medical research (3) 3
medicine & public health (3) 3
medicine, experimental (3) 3
molecular weight (3) 3
nuclear experiment (3) 3
physics of elementary particles and fields (3) 3
physics, particles & fields (3) 3
prospective studies (3) 3
rural development (3) 3
usage (3) 3
610 medicine & health (2) 2
aged, 80 and over (2) 2
agriculture, multidisciplinary (2) 2
algorithms (2) 2
amphotericin-b (2) 2
anesthesiology (2) 2
angiogenesis inhibitors - pharmacokinetics (2) 2
anti-angiogenic therapy (2) 2
antibodies, monoclonal - pharmacokinetics (2) 2
anticoagulants (2) 2
antineoplastic combined chemotherapy protocols - pharmacokinetics (2) 2
antitumor activity (2) 2
antitumor-activity (2) 2
aspergillosis (2) 2
astronomy & astrophysics (2) 2
astronomy, astrophysics and cosmology (2) 2
behavior (2) 2
biomarkers (2) 2
chemotherapy (2) 2
computer science, interdisciplinary applications (2) 2
cross-section (2) 2
disease progression (2) 2
dose-escalation (2) 2
dose-response relationship, drug (2) 2
drug interactions (2) 2
end-stage renal disease (2) 2
enoxaparin (2) 2
equipment and supplies (2) 2
equipment design (2) 2
fungal infections (2) 2
glioblastoma - drug therapy (2) 2
gliomas (2) 2
hemodialysis (2) 2
hemorrhage (2) 2
high energy physics (2) 2
hypertension (2) 2
image processing (2) 2
intensive / critical care medicine (2) 2
intravenous administration (2) 2
ischemia (2) 2
itraconazole (2) 2
luminosity (2) 2
machine vision (2) 2
mass spectrometry (2) 2
metabolism (2) 2
mice (2) 2
microbiology (2) 2
monoclonal antibodies (2) 2
multidisciplinary sciences (2) 2
mutation (2) 2
mycoses (2) 2
nephrology (2) 2
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (67) 67
French (6) 6
Chinese (1) 1
German (1) 1
Korean (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 4/2016, Volume 113, Issue 16, pp. 4476 - 4481
Inhibition of the vascular endothelial growth factor (VEGF) pathway has failed to improve overall survival of patients with glioblastoma (GBM). We previously... 
Anti-angiogenic therapy | Macrophage polarization | Tumor microenvironment | Microglia reprogramming | Anti-tumor immunity | anti-angiogenic therapy | BEVACIZUMAB | MULTIDISCIPLINARY SCIENCES | macrophage polarization | RANDOMIZED-TRIAL | ANGIOPOIETIN-2 | CANCER | THERAPY | microglia reprogramming | TIE2-EXPRESSING MONOCYTES | BLOOD-VESSELS | TUMOR-ASSOCIATED MACROPHAGES | tumor microenvironment | NORMALIZATION | anti-tumor immunity | ENDOTHELIAL GROWTH-FACTOR | Macrophages - pathology | Antibodies, Bispecific - pharmacology | Vesicular Transport Proteins - metabolism | Humans | Neoplasm Proteins - antagonists & inhibitors | Vascular Endothelial Growth Factor A - metabolism | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Neoplasm Proteins - metabolism | Neoplasms, Experimental - pathology | Xenograft Model Antitumor Assays | Macrophages - metabolism | Vesicular Transport Proteins - antagonists & inhibitors | Animals | Antibodies, Neoplasm - pharmacology | Ribonuclease, Pancreatic - metabolism | Glioblastoma - pathology | Cell Line, Tumor | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Mice | Neoplasms, Experimental - metabolism | Glioblastoma - drug therapy | Ribonuclease, Pancreatic - antagonists & inhibitors | Neoplasms, Experimental - drug therapy | Viral antibodies | Care and treatment | Antibodies | Physiological aspects | Models | Macrophages | Vascular endothelial growth factor | Health aspects | Glioblastoma multiforme | Genotype & phenotype | Survival analysis | Protein expression | Cells | Tumors | Cancer | Index Medicus | Biological Sciences
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2018, Volume 24, Issue 7, pp. 1536 - 1545
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2017, Volume 79, Issue 4, pp. 661 - 671
Journal Article
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2017, Volume 35, Issue 15_suppl, pp. e15108 - e15108
Conference Proceeding
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2016, Volume 34, Issue 15, pp. e17042 - e17042
Conference Proceeding
Neuro-Oncology, ISSN 1522-8517, 07/2015, Volume 17, Issue 7, pp. 1007 - 1015
Background. We conducted a phase 1 dose-escalation study of RO5323441, a novel antiplacental growth factor (PlGF) monoclonal antibody, to establish the... 
placental growth factor | glioblastoma | dose-escalation study | RO5323441 | Bevacizumab | GLIOMAS | ANGIOGENESIS | EFFICACY | PGF ISOFORMS | RECEPTOR | CANCER | CLINICAL NEUROLOGY | PREDICTION | ONCOLOGY | SINGLE-AGENT BEVACIZUMAB | bevacizumab | PLGF | PROGRESSION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Antibodies, Monoclonal - therapeutic use | Male | Neoplasm Recurrence, Local - mortality | Pregnancy Proteins - blood | Angiogenesis Inhibitors - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Brain Neoplasms - mortality | Angiogenesis Inhibitors - adverse effects | Bevacizumab - administration & dosage | Kaplan-Meier Estimate | Antibodies, Monoclonal - pharmacokinetics | Treatment Outcome | Angiogenesis Inhibitors - pharmacokinetics | Brain Neoplasms - drug therapy | Pregnancy Proteins - immunology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Placenta Growth Factor | Aged | Glioblastoma - drug therapy | Glioblastoma - mortality | Index Medicus | glioblastoma, placental growth factor | Clinical Investigations
Journal Article
Cancer Medicine, ISSN 2045-7634, 08/2017, Volume 6, Issue 8, pp. 1904 - 1914
To establish the maximum tolerated dose ( MTD ), dose‐limiting toxicities ( DLT ), safety profile, and anti‐tumor efficacy of RAF 265. We conducted a... 
wild‐type | Biomarker analysis | BRAF | RAF265 | mutant | metastatic melanoma | Metastatic melanoma | BRAF wild-type | BRAF-mutant | CARBOPLATIN | IMPROVED SURVIVAL | ANTITUMOR-ACTIVITY | COMBINATION | SORAFENIB | RENAL-CELL CARCINOMA | MEK INHIBITION | ONCOLOGY | CANCER STATISTICS | ENDOTHELIAL GROWTH-FACTOR | VEMURAFENIB | Humans | Middle Aged | Imidazoles - administration & dosage | Pyridines - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Imidazoles - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Neoplasm Metastasis | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Melanoma - genetics | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Imidazoles - therapeutic use | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Imidazoles - adverse effects | Treatment Outcome | Melanoma - pathology | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Biomarkers | Aged | Mutation | Drug Monitoring | Neoplasm Staging | Melanoma - mortality | Immunohistochemistry | Antigens | PET imaging | Endothelial growth factors | Gene mutations | Analysis | Melanoma | Diarrhea | Metastasis | Tumor proteins | Pharmacodynamics | Immunomodulation | Extracellular signal-regulated kinase | Raf protein | Metabolism | Metabolic response | Vascular endothelial growth factor receptors | Metastases | Angiogenesis | Placenta | Antitumor activity | Angiogenesis inhibitors | Vascular endothelial growth factor receptor 2 | Growth factors | Vascular endothelial growth factor | Index Medicus
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 05/2015, Volume 33, Issue 15, pp. 5549 - 5549
Conference Proceeding
Cancer Research, ISSN 0008-5472, 07/2017, Volume 77, Issue 13 Supplement, pp. 1803 - 1803
Journal Article
by Aad, G and Abbott, B and Abbott, D C and Abdinov, O and Abed Abud, A and Abeling, K and Abhayasinghe, D K and Abidi, S H and AbouZeid, O S and Abraham, N L and Abramowicz, H and Abreu, H and Abulaiti, Y and Acharya, B S and Achkar, B and Adachi, S and Adam, L and Adam Bourdarios, C and Adamczyk, L and Adamek, L and Adelman, J and Adersberger, M and Adiguzel, A and Adorni, S and Adye, T and Affolder, A A and Afik, Y and Agapopoulou, C and Agaras, M N and Aggarwal, A and Agheorghiesei, C and Aguilar-Saavedra, J A and Ahmadov, F and Ahmed, W S and Ai, X and Aielli, G and Akatsuka, S and Åkesson, T P A and Akilli, E and Akimov, A V and Al Khoury, K and Alberghi, G L and Albert, J and Alconada Verzini, M J and Alderweireldt, S and Aleksa, M and Aleksandrov, I N and Alexa, C and Alexandre, D and Alexopoulos, T and Alfonsi, A and Alhroob, M and Ali, B and Alimonti, G and Alison, J and Alkire, S P and Allaire, C and Allbrooke, B M M and Allen, B W and Allport, P P and Aloisio, A and Alonso, A and Alonso, F and Alpigiani, C and Alshehri, A A and Alvarez Estevez, M and Álvarez Piqueras, D and Alviggi, M G and Amaral Coutinho, Y and Ambler, A and Ambroz, L and Amelung, C and Amidei, D and Amor Dos Santos, S P and Amoroso, S and Amrouche, C S and An, F and Anastopoulos, C and Andari, N and Andeen, T and Anders, C F and Anders, J K and Andreazza, A and Andrei, V and Anelli, C R and Angelidakis, S and Angerami, A and Anisenkov, A V and Annovi, A and Antel, C and Anthony, M T and Antonelli, M and Antrim, D J A and Anulli, F and Aoki, M and Aparisi Pozo, J A and Aperio Bella, L and Arabidze, G and Araque, J P and Araujo Ferraz, V and ... and ATLAS Collaboration and Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Physical review letters, ISSN 0031-9007, 08/2019, Volume 123, Issue 5, pp. 052001 - 052001
This Letter describes the observation of the light-by-light scattering process, γγ→γγ, in Pb+Pb collisions at sqrt[s_{NN}]=5.02  TeV. The analysis is conducted... 
Luminosity | Collisions | Light scattering | Light | Transverse momentum | Index Medicus | PHYSICS OF ELEMENTARY PARTICLES AND FIELDS
Journal Article
by Aad, G and Abbott, B and Abbott, D.C and Abdinov, O and Abed Abud, A and Abeling, K and Abhayasinghe, D.K and Abidi, S.H and AbouZeid, O.S and Abraham, N.L and Abramowicz, H and Abreu, H and Abulaiti, Y and Acharya, B.S and Achkar, B and Adachi, S and Adam, L and Adam Bourdarios, C and Adamczyk, L and Adamek, L and Adelman, J and Adersberger, M and Adiguzel, A and Adorni, S and Adye, T and Affolder, A.A and Afik, Y and Agapopoulou, C and Agaras, M.N and Aggarwal, A and Agheorghiesei, C and Aguilar-Saavedra, J.A and Ahmadov, F and Ahmed, W.S and Ai, X and Aielli, G and Akatsuka, S and Åkesson, T.P.A and Akilli, E and Akimov, A.V and Al Khoury, K and Alberghi, G.L and Albert, J and Alconada Verzini, M.J and Alderweireldt, S and Aleksa, M and Aleksandrov, I.N and Alexa, C and Alexandre, D and Alexopoulos, T and Alfonsi, A and Alhroob, M and Ali, B and Alimonti, G and Alison, J and Alkire, S.P and Allaire, C and Allbrooke, B.M.M and Allen, B.W and Allport, P.P and Aloisio, A and Alonso, A and Alonso, F and Alpigiani, C and Alshehri, A.A and Alvarez Estevez, M and Alvarez Gonzalez, B and Álvarez Piqueras, D and Alviggi, M.G and Amaral Coutinho, Y and Ambler, A and Ambroz, L and Amelung, C and Amidei, D and Amor Dos Santos, S.P and Amoroso, S and Amrouche, C.S and An, F and Anastopoulos, C and Andari, N and Andeen, T and Anders, J.K and Anders, C.F and Andreazza, A and Andrei, V and Anelli, C.R and Angelidakis, S and Angerami, A and Anisenkov, A.V and Annovi, A and Antel, C and Anthony, M.T and Antonelli, M and Antrim, D.J.A and Anulli, F and Aoki, M and Aparisi Pozo, J.A and Aperio Bella, L and Arabidze, G and Araque, J.P and ... and Lawrence Berkeley National Lab. (LBNL), Berkeley, CA (United States)
Physics Letters B, ISSN 0370-2693, 09/2019, Volume 796, Issue C, pp. 68 - 87
A search for high-mass dielectron and dimuon resonances in the mass range of 250 GeV to 6 TeV is presented. The data were recorded by the ATLAS experiment in... 
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 12/2015, Volume 14, Issue 12 Supplement 2, pp. C125 - C125
Journal Article